WebMay 11, 2024 · Roche announced Wednesday that the Phase III SKYSCRAPER-01 study investigating the experimental anti-TIGIT immunotherapy tiragolumab plus the PD-L1 inhibitor Tecentriq (atezolizumab) in certain patients with non-small-cell lung cancer (NSCLC) failed to meet its co-primary endpoint of progression-free survival (PFS). WebMay 12, 2024 · Roche announced that the Phase 3 SKYSCRAPER-01 study of its investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) did not meet the co-primary endpoint of progression-free survival (PFS). The Phase 3 trial evaluated the tiragolumab plus Tecentriq in 534 patients with first-line PD-L1-high metastatic non …
JP Morgan Healthcare Conference, Day 2: Roche, Zai Lab, …
WebMar 4, 2024 · Symptomatic, untreated, or actively progressing central nervous system metastases. Active or history of autoimmune disease or immune deficiency. History of … WebRoche is a large crater on the far side of the Moon from the Earth.The prominent crater Pauli lies across the southern rim of Roche, and the outer rampart of Pauli covers a portion of … dentist in exmouth
Interim results for phase III SKYSCRAPER-01 study in PD-L1-high ...
WebRoche Tower (German: Roche-Turm) is a skyscraper in the Swiss city of Basel. At 178 metres, it is the second tallest building in the country. The building, also known as … WebMay 11, 2024 · The phase 3 trial, dubbed SKYSCRAPER-01, evaluated anti-TIGIT immunotherapy tiragolumab plus Roche's blockbuster drug Tecentriq (atezolizumab) against Tecentriq alone as an initial treatment... WebMar 30, 2024 · The Phase III SKYSCRAPER-01 trial is currently ongoing to confirm the CITYSCAPE results. Since 2024, Genentech has initiated five Phase III trials, including NSCLC (SKYSCRAPER-01, SKYSCRAPER-03), ES-SCLC (SKYSCRAPER-02), esophageal cancers (SKYSCRAPER-07, SKYSCRAPER-08), and multiple early trials in various tumor … dentist in fairbury ne